Clinical trials: Thinning Hair
Alopecia, Baldness
Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss.
- Trial name
- NCT01325350
- Testing
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Where
- 2 sites in United States, Germany
- Volunteers
- 306 people
- Sponsor
- Allergan
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
This study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of N1087 compared with placebo in adult men with androgenetic alopecia (male pattern hair loss).
- Trial name
- MINORA-MEN (NCT07529977)
- Testing
- Minoxidil oral solution
- Volunteers
- 372 people
- Sponsor
- Eurofarma Laboratorios S.A.
Severe Alopecia Areata
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
The purpose of this observation study is to learn about the safety and effects of the study medicine (called Litfulo) for the potential treatment of Severe Alopecia Areata.
- Trial name
- NCT07152119
- Testing
- Litfulo
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Pfizer
Alopecia Areata
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
Primary: To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA) Secondary: To evaluate key clinical outcome assessments
- Trial name
- NCT03354637
- Testing
- ATI-50002 high dose, ATI-50002 low dose
- Where
- 23 sites in United States
- Volunteers
- 129 people
- Sponsor
- Aclaris Therapeutics, Inc.
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenic Alopecia
Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia
The CSP-001-FOL1 clinical study is aimed to investigate whether local topical administration of FOL100 lotion will be safe for the patient and will not cause local or systemic skin or other adverse events.
- Trial name
- NCT05611593
- Testing
- FOL100, Propecia 1Mg Tablet
- Where
- 3 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Follicle Pharma Ltd
Alopecia Areata
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur.
- Trial name
- NCT07533006
- Testing
- LY4005130
- Where
- 30 sites in United States, Canada and 5 more
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
Androgenetic Alopecia
Phase III Study of KX-826 With Adult Male Patients With AGA
This is a phase III, multi-center, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of KX-826 for topical use in Chinese adult male patients with androgenetic alopecia (AGA).
- Trial name
- NCT06126965
- Testing
- KX-826-（5%） BID
- Where
- 26 sites in China
- Volunteers
- 740 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Alopecia Areata
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.
- Trial name
- NCT02553330
- Testing
- Ruxolitinib Phosphate Cream
- Where
- 18 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Alopecia, Androgenetic
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
- Trial name
- SCALP1 (NCT05910450)
- Testing
- Clascoterone 5% solution, Vehicle solution
- Where
- 24 sites in United States, Georgia
- Volunteers
- 703 people
- Sponsor
- Cassiopea SpA
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Androgenetic Alopecia
XVIE to Treat Androgenetic Alopecia (AGA)
This study tests whether XVIE, an investigational injectable product made from processed human amniotic fluid, is safe and may help regrow hair in adults with androgenetic alopecia (common pattern hair loss).
- Trial name
- NCT07482423
- Testing
- Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.
- Trial name
- NCT02279823
- Testing
- CB-03-01 solution, Minoxidil Solution 5%
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- Intrepid Therapeutics, Inc.
Androgenetic Alopecia
Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients
This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr.
- Trial name
- NCT07429253
- Testing
- Secretome, Platelet-Rich Plasma (PRP) Injections
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Hypertrichosis, Alopecia
Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth
A study to investigate clinical safety and effect on hair growth of FOL-005 in healthy volunteers. The study is divided in two parts, a single ascending dose (SAD) part and a multiple dose (MD) part.
- Conditions
- Hypertrichosis, Alopecia, Hirsutism
- Trial name
- NCT02793557
- Testing
- FOL-005
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Follicum AB
Alopecia, Alopecia, Androgenetic
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01904721
- Testing
- Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- Allergan
Alopecia Areata
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).
- Trial name
- Allegro2a (NCT04517864)
- Testing
- PF-06651600
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Hair Thinning
Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair
The objective of this study is to assess the effectiveness and safety of a novel dietary supplement containing botanical ingredients for hair thinning in men over the course of six months of continuous daily usage.
- Trial name
- NCT05339958
- Testing
- Nutrafol® Men Hair Growth Nutraceutical
- Where
- 2 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Nutraceutical Wellness Inc.
Prevention of Chemotherapy-induced Myelosuppression
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
This is a Phase 1b open-label, single arm, multicenter, study of ALRN-6924 as a chemoprotection agent in patients with TP53-mutated HER2- breast cancer (stages IIa to IIIb) receiving neoadjuvant or adjuvant chemotherapy with…
- Trial name
- NCT05622058
- Testing
- ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
- Where
- 14 sites in United States, Bosnia and Herzegovina and 2 more
- Volunteers
- 6 people
- Sponsor
- Aileron Therapeutics, Inc.
Chemotherapy Induced Alopecia, Chemotherapy Side Effects
Pharmacokinetic Study of DA-020
Pharmacokinetic Study of DA-020
- Trial name
- NCT07402330
- Testing
- DA-020 (0.1%), DA-020 (0.2%), DA-020 (0.5%)
- Where
- 2 sites in Brazil, Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Applied Biology, Inc.